PRESS RELEASE: PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment

cnb982 inipharm pr promo bar v1 |
Learn more
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment

      • OBN Awards 2023 winner!

      • CN Bio appoints Neil Rumbelow as Director of Product Development

      View all news

      Upcoming Events

      Check back soon for upcoming events

      View all events

      Join the team!

      • Director of Sales – Americas Region

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Harnessing the power of multimodal imaging to explore ASO distribution in cells, complex in vitro models and tissue

May 6, 2022

Resource > Posters >

Harnessing the power of multimodal imaging to explore ASO distribution in cells, complex in vitro models and tissue

Filed under: ADME, Drug absorption, and Drug metabolism

Harnessing the power of multimodal imaging to explore ASO distribution in cells EDIT |

Video content if present

Alex et al

Further advancement of antisense oligonucleotides (ASOs) in the clinic urgently requires optimization of ASO delivery, target engagement, and safety profile within human-relevant in vitro and ex-vivo systems.

This recent poster from GSK and collaborators features data from our PhysioMimix® OOC and Liver plates. The results demonstrate that the distribution of ASOs into Kupffer cells and circular or cuboidal hepatocytes cultured in 3D can be detected using imaging.

Preliminary results can be found in the poster, with the full set due to be published later this year.

Video content if present

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment December 4, 2023
  • OBN Awards 2023 winner! November 23, 2023
  • CN Bio appoints Neil Rumbelow as Director of Product Development November 2, 2023

Upcoming events